Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer-Reference-Cited by-同舟云学术

Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer

Published:1995-04 Issue:2 Volume:4 Page:189-202
ISSN:1055-3207
Container-title:Surgical Oncology Clinics of North America
language:en
Short-container-title:Surgical Oncology Clinics of North America

Author:

O’Donnell Michael A.,DeWolf William C.

Publisher

Elsevier BV

Subject

Oncology,Surgery

Reference102 articles.

1. Immunity to tumors;Abbas,1991

2. Evidence for a multistep mechanism of cytolysis by BCG-activated macrophages: The interrelationship between the capacity for cytolysis, target binding, and secretion of cytolytic factor;Adams;J Immunol,1992

3. Humoral and cell-mediated cell responses to live recombinant BCG-HIV vaccines;Aldovini;Nature,1991

4. American Cancer Society 1994 Facts and Figures. American Cancer Society, 1994

5. Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer;Azaka;J Urol,1991

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder Cancer;European Urology Supplements;2010-12

2. Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma;Cancer Gene Therapy;2010-09-17

3. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette–Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells;Clinical and Experimental Immunology;2010-02-10

4. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy;Immunopharmacology and Immunotoxicology;2010-01-27

5. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro;Cancer Immunology, Immunotherapy;2009-02-13